Giving the latest update on its web site, Germany's Bayer says that it has now settled 2,933 law suits related to its withdrawn cholesterol-lowering drug Lipobay/Baycol (cerivastatin) in which it has paid more than $1.11 billion in out-of-court agreements.
The drug was taken off the market in 2001 after it was linked with causing the muscle-wasting disease rhabdomylosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze